In an attempt to bolster its presence in respiratory disorders, Sanofi has agreed to acquire Vicebio for a total deal value of up to US$1.6 B. Through this acquisition, Sanofi will gain access to Vicebio’s Molecular Clamp technology as well as its lead candidate, VXB-241, which is currently undergoing a Phase I exploratory clinical trial targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3. This transaction adds to the string of M&A deals announced by the French pharma giant in 2025, further reinforcing its expansion strategy.